で公開中です！詳しく見る

Conexeu Sciences Inc

CNXU

時価総額 $8631万

3.06 USD

-0.89

22.53%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

3.15

+0.09

2.94%

1日

-22.53%

5日間

-25.37%

1か月

-33.77%

3か月

-70.88%

6か月

-76.59%

年初来

-76.59%

1年

-76.59%

5年間

-76.59%

10年間

-76.59%

概要： Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company's planned FDA 510(k) submission in the first quarter of 2027 Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company's planned FDA 510(k) submission in the first quarter of 2027

Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

ニュートラル

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today provided an update on the regulatory and manufacturing program supporting its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten Minute Tissue™, its lead wound care device candidate, as well as on the Company's broader preparations for commercialization.

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

ニュートラル

Conexeu Sciences Sets September and October 2026 Conference Schedule

RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is pleased to announce its participation in the following investor and industry conferences during September and October 2026.

Conexeu Sciences Sets September and October 2026 Conference Schedule

ニュートラル

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

ニュートラル

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

ニュートラル

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence base behind the CXU™ platform's development direction and the Company's planned move into the medical aesthetics injectable market.

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

ニュートラル

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

ポジティブ

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

ニュートラル

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

ニュートラル

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています